Comunicati Stampa
Salute e Benessere

Vistin Pharma ASA: Invitation to Q3 2024 conference call

Vistin Pharma ASA will release its third quarter and YTD 2024 results on Thursday 31st of October 2024. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Thursday 31 stof October at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The third quarter conference call will be available via web and audio through the following access points: Webcast:...
Oslo, (informazione.it - comunicati stampa - salute e benessere)


Vistin Pharma ASA will release its third quarter and YTD 2024 results on Thursday 31st of October 2024. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Thursday 31 of October at 08:30 CET. There will be a Q&A session following the management discussion.

The conference call will be held in English.

The third quarter conference call will be available via web and audio through the following access points:

Webcast: https://edge.media-server.com/mmc/p/vbrzzjjk

Telephone conference (online registration): https://register.vevent.com/register/BI809b345192f14b6882c8bda7de2220b6

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97053621
alexander.karlsen@vistin.com

About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.


 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act


Per maggiori informazioni
Ufficio Stampa
 Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
Allegati
Non disponibili